Format

Send to

Choose Destination
Adv Drug Deliv Rev. 2014 Aug;75:3-17. doi: 10.1016/j.addr.2014.03.006. Epub 2014 Apr 13.

Emerging inhalation aerosol devices and strategies: where are we headed?

Author information

1
Advanced Drug Delivery Group, Faculty of Pharmacy, The University of Sydney, Sydney, 2006 NSW, Australia.
2
Advanced Drug Delivery Group, Faculty of Pharmacy, The University of Sydney, Sydney, 2006 NSW, Australia; Respiratory Technology, Woolcock Institute of Medical Research and Discipline of Pharmacology, Sydney Medical School, The University of Sydney, 2037 NSW. Australia.
3
Advanced Drug Delivery Group, Faculty of Pharmacy, The University of Sydney, Sydney, 2006 NSW, Australia. Electronic address: kim.chan@sydney.edu.au.

Abstract

Novel inhaled therapeutics including antibiotics, vaccines and anti-hypertensives, have led to innovations in designing suitable delivery systems. These emerging design technologies are in urgent demand to ensure high aerosolisation performance, consistent efficacy and satisfactory patient adherence. Recent vibrating-mesh and software technologies have resulted in nebulisers that have remarkably accurate dosing and portability. Alternatively, dry powder inhalers (DPIs) have become highly favourable for delivering high-dose and single-dose drugs with the aid of advanced particle engineering. In contrast, innovations are needed to overcome the technical constrains in drug-propellant incompatibility and delivering high-dose drugs with pressurised metered dose inhalers (pMDIs). This review discusses recent and emerging trends in pulmonary drug delivery systems.

KEYWORDS:

Computational modelling; Dry powder inhaler; Inhalation therapy; Nebuliser; Particle engineering; Patient adherence; Pressurised metered dose inhaler; Pulmonary drug delivery

PMID:
24732364
DOI:
10.1016/j.addr.2014.03.006
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center